Association between free light chain levels, and disease progression and mortality in chronic kidney disease

Toxins

Volumn 5, Issue 11, 2013, Pages 2058-2073

  Desjardins, Lucie ^a,b   Liabeuf, Sophie ^a,b   Lenglet, Aurélie ^a,c   Lemke, Horst Dieter ^d   Vanholder, Raymond ^e   Choukroun, Gabriel ^a,c   Massy, Ziad A ^a,f  

^a INSERM   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d eXcorLab GmbH   (Germany)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Chronic kidney disease; Free light chain; Uremic toxins

Indexed keywords

BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN;

ADULT; AGE; ARTICLE; BIOCHEMISTRY; CALCIFICATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEMODIALYSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT MONITORING;

AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TOXINS, BIOLOGICAL;

EID: 84887594069     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins5112058     Document Type: Article

References (27)

1. Vanholder, R.; de Smet, R.; Glorieux, G.; Argiles, A.; Baurmeister, U.; Brunet, P.; Clark, W.; Cohen, G.; de Deyn, P.P.; Deppisch, R.; et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int. 2003, 63, 1934-1943.
2. Dispenzieri, A.; Kyle, R.; Merlini, G.; Miguel, J.S.; Ludwig, H.; Hajek, R.; Palumbo, A.; Jagannath, S.; Blade, J.; Lonial, S.; et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2008, 23, 215-224.
3. Katzmann, J.A.; Abraham, R.S.; Dispenzieri, A.; Lust, J.A.; Kyle, R.A. Diagnostic performance of quantitative κ and λ free light chain assays in clinical practice. Clin. Chem. 2005, 51, 878-881.
4. Solomon, A. Light chains of human immunoglobulins. Methods Enzymol. 1985, 116, 101-121.
5. Hutchison, C.A.; Harding, S.; Hewins, P.; Mead, G.P.; Townsend, J.; Bradwell, A.R.; Cockwell, P. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2008, 3, 1684-1690.
6. Herrera, G.A. Renal lesions associated with plasma cell dyscrasias: Practical approach to diagnosis, new concepts, and challenges. Arch. Pathol. Lab. Med. 2009, 133, 249-267.
7. Kapur, U.; Barton, K.; Fresco, R.; Leehey, D.J.; Leehy, D.J.; Picken, M.M. Expanding the pathologic spectrum of immunoglobulin light chain proximal tubulopathy. Arch. Pathol. Lab. Med. 2007, 131, 1368-1372.
8. Haynes, R.; Hutchison, C.A.; Emberson, J.; Dasgupta, T.; Wheeler, D.C.; Townend, J.N.; Landray, M.J.; Cockwell, P. Serum free light chains and the risk of ESRD and death in CKD. Clin. J. Am. Soc. Nephrol. 2011, 6, 2829-2837.
9. Martin, W.; Abraham, R.; Shanafelt, T.; Clark, R.J.; Bone, N.; Geyer, S.M.; Katzmann, J.A.; Bradwell, A.; Kay, N.E.; Witzig, T.E. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl. Res. 2007, 149, 231-235.
10. Cohen, G.; Rudnicki, M.; Schmaldienst, S.; Hörl, W.H. Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients. Nephrol. Dial. Transplant. 2002, 17, 879-883.
11. Cohen, G.; Haag-Weber, M.; Mai, B.; Deicher, R.; Hörl, W.H. Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. J. Am. Soc. Nephrol. 1995, 6, 1592-1599.
12. Cohen, G.; Rudnicki, M.; Höorl, W.H. Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils. Kidney Int. 2001, 59, S48-S52.
13. Tonelli, M.; Sacks, F.; Pfeffer, M.; Jhangri, G.S.; Curhan, G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005, 68, 237-245.
14. Shlipak, M.G.; Fried, L.F.; Crump, C.; Bleyer, A.J.; Manolio, T.A.; Tracy, R.P.; Furberg, C.D.; Psaty, B.M. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003, 107, 87-92.
15. Cheung, A.K.; Rocco, M.V.; Yan, G.; Leypoldt, J.K.; Levin, N.W.; Greene, T.; Agodoa, L.; Bailey, J.; Beck, G.J.; Clark, W.; et al. Serum β-2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO study. J. Am. Soc. Nephrol. 2006, 17, 546-555.
16. Kim, K.M.; Kim, S.-S.; Kim, H.; Koo, T.; Im, E.Y.; Kim, S.B. Higher serum beta2-microglobulin levels are associated with better survival in chronic hemodialysis patients: A reverse epidemiology. Clin. Nephrol. 2011, 75, 458-465.
17. Liabeuf, S.; Lenglet, A.; Desjardins, L.; Neirynck, N.; Glorieux, G.; Lemke, H.-D.; Vanholder, R.; Diouf, M.; Choukroun, G.; Massy, Z.A. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int. 2012, 82, 1297-1303.
18. Astor, B.C.; Muth, B.; Kaufman, D.B.; Pirsch, J.D.; Michael Hofmann, R.; Djamali, A. Serum β2-microglobulin at discharge predicts mortality and graft loss following kidney transplantation. Kidney Int. 2013, 84, 810-817.
19. Foster, M.C.; Inker, L.A.; Levey, A.S.; Selvin, E.; Eckfeldt, J.; Juraschek, S.P.; Coresh, J. Novel filtration markers as predictors of all-cause and cardiovascular mortality in US adults. Am. J. Kidney Dis. 2013, 62, 42-51.
20. Meert, N.; Eloot, S.; Waterloos, M.-A.; Landschoot, M.V.; Dhondt, A.; Glorieux, G.; Ledebo, I.; Vanholder, R. Effective removal of protein-bound uraemic solutes by different convective strategies: A prospective trial. Nephrol. Dial. Transplant. 2009, 24, 562-570.
21. Stevens, L.A.; Coresh, J.; Schmid, C.H.; Feldman, H.I.; Froissart, M.; Kusek, J.; Rossert, J.; Van Lente, F.; Bruce, R.D.; Zhang, Y.L.; et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3418 individuals With CKD. Am. J. Kidney Dis. 2008, 51, 395-406.
22. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39, S1-S266.
23. Zureik, M.; Temmar, M.; Adamopoulos, C.; Bureau, J.-M.; Courbon, D.; Thomas, F.; Bean, K.; Touboul, P.-J.; Ducimetière, P.; Benetos, A. Carotid plaques, but not common carotid intima-media thickness, are independently associated with aortic stiffness. J. Hypertens. 2002, 20, 85-93.
24. Asmar, R.; Benetos, A.; Topouchian, J.; Laurent, P.; Pannier, B.; Brisac, A.M.; Target, R.; Levy, B.I. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995, 26, 485-490.
25. Kauppila, L.I.; Polak, J.F.; Cupples, L.A.; Hannan, M.T.; Kiel, D.P.; Wilson, P.W. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: A 25-year follow-up study. Atherosclerosis 1997, 132, 245-250.
26. Agatston, A.S.; Janowitz, W.R.; Hildner, F.J.; Zusmer, N.R.; Viamonte, M., Jr.; Detrano, R. Quantification of coronary artery calcium using ultrafast computed tomography. J. Am. Coll. Cardiol. 1990, 15, 827-832.
27. Rosenbaum, P.R.; Rubin, D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70, 41-55.